PET 18F-flurpridaz quantitative measurements of myocardial blood flow: Added value for diagnosis of coronary artery disease? Of course!
PET 18F-flurpridaz quantitative measurements of myocardial blood flow: Added value for diagnosis of coronary artery disease? Of course!
复制标题
PET 18F-flupridaz 定量测量心肌血流量:对诊断冠状动脉疾病的附加值?
DOI:
10.1007/s12350-020-02043-1
复制
发表时间:
2020
影响因子:
2.4
通讯作者:
H. Gewirtz
中科院分区:
文献类型:
--
作者:
H. Gewirtz
In the current issue of the Journal, Moody et al report the results of a retrospective analysis of Fflurpiridaz (FPZ), PET quantitative measurements of myocardial blood flow (MBF) for diagnosis of coronary artery disease (CAD). Patients (n = 231) were clinically stable and selected from a larger group enrolled in the flurpridaz 301 trial (n = 755; NCT01347710). All participants were able to undergo either an exercise or vasodilator stress test for clinically indicated SPECT myocardial perfusion imaging (MPI). The sub-study was not pre-specified and required availability of dynamic PET data of sufficient technical quality to obtain quantitative PET MBF measurements. PET data processing and analysis was performed using Corridor4DM software (V 2017; INVIA Medical Imaging Solutions, Ann Arbor, MI). The gold standard comparator was quantitative, percent diameter, stenosis (QCA) as determined from invasive coronary angiography (ICA; 50% and 70% criteria considered). While ICA information was available on all patients, FFR data were not. The data analysis was exhaustive (8 figures and as many equally comprehensive tables) with similar supplemental data submitted as that in the body of the paper. Accordingly, the editorial will to focus only on key highlights as well as some limitations of the work.
影响因子:
20.1
作者:
Deyell MW;Krahn AD;Goldberger JJ
通讯作者:
Goldberger JJ